吉西他滨预处理的晚期胰腺癌患者的二线治疗 - Suppr

Second-line therapy in gemcitabine-pretreated patients with advanced pancreatic cancer.

作者信息

Boeck Stefan, Heinemann Volker

出版信息

J Clin Oncol. 2008 Mar 1;26(7):1178-9; author reply 1179. doi: 10.1200/JCO.2007.15.3304.

DOI:10.1200/JCO.2007.15.3304

PMID:18309957

Abstract

摘要

相似文献

Second-line therapy in gemcitabine-pretreated patients with advanced pancreatic cancer.

J Clin Oncol. 2008 Mar 1;26(7):1178-9; author reply 1179. doi: 10.1200/JCO.2007.15.3304.

The role of second-line chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer.

Future Oncol. 2008 Feb;4(1):41-50. doi: 10.2217/14796694.4.1.41.

Gemcitabine doublets in advanced pancreatic cancer: should we move on?

J Clin Oncol. 2006 Jan 20;24(3):327-9. doi: 10.1200/JCO.2005.03.8315. Epub 2005 Dec 12.

Will gemcitabine monotherapy be dethroned as the adjuvant chemotherapy in pancreatic adenocarcinoma?

Future Oncol. 2017 Feb;13(3):197-199. doi: 10.2217/fon-2016-0316. Epub 2016 Sep 14.

Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.

Invest New Drugs. 2005 Aug;23(4):369-75. doi: 10.1007/s10637-005-1446-y.

[Chemoradiation for pancreatic adenocarcinoma].

Cancer Radiother. 2004 Nov;8 Suppl 1:S80-7.

[Salvage chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer: survival benefit in selected patients].

Korean J Gastroenterol. 2008 Jul;52(1):59-63.

[Recent Advances in Palliative Chemotherapy for Unresectable Pancreatic Cancer].

Korean J Gastroenterol. 2015 Sep;66(3):150-3. doi: 10.4166/kjg.2015.66.3.150.

[Gemcitabine and pancreatic cancer].

Bull Cancer. 2002 Aug;89 Spec No:S91-5.

Achieving the best of both worlds.

J Clin Oncol. 2013 Jan 1;31(1):3-4. doi: 10.1200/JCO.2012.46.4891. Epub 2012 Dec 3.

引用本文的文献

Analysis of Clinical Predictive Factors Affecting the Outcome of Second-Line Chemotherapy for Gemcitabine-Refractory Advanced Pancreatic Cancer.

Gut Liver. 2020 Jan 15;14(1):135-143. doi: 10.5009/gnl18419.

Use of gemcitabine as a second-line treatment following chemotherapy with folfirinox for metastatic pancreatic adenocarcinoma.

Oncol Lett. 2017 Jun;13(6):4917-4924. doi: 10.3892/ol.2017.6061. Epub 2017 Apr 20.

TTD consensus document on the diagnosis and management of exocrine pancreatic cancer.

Clin Transl Oncol. 2014 Oct;16(10):865-78. doi: 10.1007/s12094-014-1177-7. Epub 2014 Apr 12.

Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer.

World J Gastroenterol. 2012 Mar 28;18(12):1357-64. doi: 10.3748/wjg.v18.i12.1357.

Advanced pancreatic carcinoma: current treatment and future challenges.

Nat Rev Clin Oncol. 2010 Mar;7(3):163-72. doi: 10.1038/nrclinonc.2009.236. Epub 2010 Jan 26.

Accomplishments in 2008 in the treatment of metastatic pancreatic cancer.

Gastrointest Cancer Res. 2009 Sep;3(5 Supplement 2):S43-7.

A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer.

Br J Cancer. 2009 Nov 17;101(10):1658-63. doi: 10.1038/sj.bjc.6605374. Epub 2009 Oct 13.

Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma.

Oncogene. 2009 Aug 13;28(32):2903-9. doi: 10.1038/onc.2009.158. Epub 2009 Jun 22.

A phase II study of flavopiridol (Alvocidib) in combination with docetaxel in refractory, metastatic pancreatic cancer.

Pancreatology. 2009;9(4):404-9. doi: 10.1159/000187135. Epub 2009 May 19.

[Medical-oncological aspects in the treatment of pancreatic cancer].

Radiologe. 2009 Feb;49(2):144-8. doi: 10.1007/s00117-008-1753-3.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Second-line therapy in gemcitabine-pretreated patients with advanced pancreatic cancer.

作者信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献